srch

22.08.2021 · BERGENBIO ASA: LEADERSHIP CHANGE. 22.08.2021. Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021.

BerGenBio er et biotekonoligiselskap som fokuserer på kreftforskning. De forsker på legemidler som skal blant annet kunne stoppe kreft fra å spre seg, ...

Kjøp BERGENBIO (BGBIO) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid

Ticker: BGBIO. BerGenBio er et bioteknologiselskap i klinisk fase med fokus på å utvikle ledende legemiddelkandidater mot de fleste aggressive kreftformer.

BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers.

Bergenbio ASA is Norway-based company that provides technology platforms used in the research and pre-clinical development of drug targets, associated ...

Feb 16, 2022 · Bergenbio ASA is Norway-based company that provides technology platforms used in the research and pre-clinical development of drug targets, associated biomarkers and therapeutics for the treatment of cancer. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors ...

Bergenbio tapte 69 millioner kroner i fjerdekvartal 2021. Legemiddel- og bioteknologi-selskapet Bergenbio tapte 69 millioner kroner i resultat før skatt i fjerdekvartal 2021. Det fremkommer av selskapets kvartalsrapport som ble offentliggjort onsdag morgen. Tapet i kvartalet er fem millioner forbedring fra samme kvartal i 2020 da underskuddet ...

Kjøp BERGENBIO (BGBIO) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid.

bergenbio asa (ose: bgbio), a clinical-stage biopharmaceutical company developing novel, selective axl inhibitors for severe unmet medical needs, today announces that the u.s. food and drug...

12.09.2020 · Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 09:19: INNSIDER OG CEO kjøper seg opp i BERGENBIO 6915 klaesp 02.02.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 13:31: WhatsUp with BerGenBio? 26008 Move Along 31.01.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 10:53: Covid og BerGenBio 2775 A-Spekulant1 12.01.2022 ...

Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 14:25: Bergenbio nær gjennombrudd? 2175 prikken 09.12.2019; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 09:57: News Bergen Bio 4040 mynten1 05.12.2019; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 19:52: BGBIO: Går til 72 i 2019 27032 Korsar 11.11.2019; Forum Ticker Siste ...

BerGenBio er et biotekonoligiselskap som fokuserer på kreftforskning. De forsker på legemidler som skal blant annet kunne stoppe kreft fra å spre seg, eller stanse kreftcellene i å bli motstandsdyktige mot kreftbehandling. Selskapets nettside. Markedsdata er levert av Infront.

SvalKapital. for 1 døgn siden · Vis innlegg. BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR Bergen, Norway, 17 March 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need.

View the latest BGBIO stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Bergenbio ASA.

04.02.2022 · BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003) BerGenBio ASA announces the completion of patient recruitment into BGBC003 (ClinicalTrials.gov ID: NCT02488408), a Phase Ib/II multicenter open-label study of bemcentinib as a single agent and in combination with cytarabine or decitabine in patients with Acute Myeloid …

BergenBio kommer til å løse Covid-19 krisen. [32], 9656, MiniMe. 04.11.2021. Forum, Ticker, Siste, Innlegg, Svar ...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, ...

BerGenBio's ticker is BGBIO... View BerGenBio ASA's Ticker trends, charts, and more.

Stock analysis for Bergenbio ASA (BGBIO:Oslo) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com Main Job Purpose: The Translational Science Associate is a cross functional role to support Translational Science objectives in BerGenBio Clinical trials.

16.12.2021 · BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth quarter and full year 2021. A briefing.

04.05.2020 · BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com *** – IMPORTANT INFORMATION – This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares.

BERGENBIO. Oslo Børs NO0010650013 - Stock. NOK 16,95. STENGT. 15.03.2022 16:25 CET. Siden åpning. -0,55 (-3,14%). Siden forrige sluttkurs. -0,35 (-2,02%).